Další formáty:
BibTeX
LaTeX
RIS
@article{1672317,
author = {Holbech, Henrik and Matthiessen, Peter and Hansen, Martin and Schuurmann, Gerrit and Knapen, Dries and Reuver, Marieke and Flamant, Frederic and Sachs, Laurent and Kloas, Werner and Hilscherová, Klára and Leonard, Marc and Arning, Juergen and Strauss, Volker and Iguchi, Taisen and Baumann, Lisa},
article_location = {Basel},
article_number = {8},
doi = {http://dx.doi.org/10.3390/ijms21082954},
keywords = {endocrine disruption; thyroid hormone disruption; AOP; adverse outcome pathway; OECD; test guideline; integrated approach to testing and assessment; IATA; cross-species extrapolation; biomarkers},
language = {eng},
issn = {1422-0067},
journal = {International Journal of Molecular Sciences},
title = {ERGO: Breaking Down the Wall between Human Health and Environmental Testing of Endocrine Disrupters},
url = {https://doi.org/10.3390/ijms21082954},
volume = {21},
year = {2020}
}
TY - JOUR
ID - 1672317
AU - Holbech, Henrik - Matthiessen, Peter - Hansen, Martin - Schuurmann, Gerrit - Knapen, Dries - Reuver, Marieke - Flamant, Frederic - Sachs, Laurent - Kloas, Werner - Hilscherová, Klára - Leonard, Marc - Arning, Juergen - Strauss, Volker - Iguchi, Taisen - Baumann, Lisa
PY - 2020
TI - ERGO: Breaking Down the Wall between Human Health and Environmental Testing of Endocrine Disrupters
JF - International Journal of Molecular Sciences
VL - 21
IS - 8
SP - 1-18
EP - 1-18
PB - Multidisciplinary Digital Publishing Institute
SN - 14220067
KW - endocrine disruption
KW - thyroid hormone disruption
KW - AOP
KW - adverse outcome pathway
KW - OECD
KW - test guideline
KW - integrated approach to testing and assessment
KW - IATA
KW - cross-species extrapolation
KW - biomarkers
UR - https://doi.org/10.3390/ijms21082954
L2 - https://doi.org/10.3390/ijms21082954
N2 - ERGO (EndocRine Guideline Optimization) is the acronym of a European Union-funded research and innovation action, that aims to break down the wall between mammalian and non-mammalian vertebrate regulatory testing of endocrine disruptors (EDs), by identifying, developing and aligning thyroid-related biomarkers and endpoints (B/E) for the linkage of effects between vertebrate classes. To achieve this, an adverse outcome pathway (AOP) network covering various modes of thyroid hormone disruption (THD) in multiple vertebrate classes will be developed. The AOP development will be based on existing and new data from in vitro and in vivo experiments with fish, amphibians and mammals, using a battery of different THDs. This will provide the scientifically plausible and evidence-based foundation for the selection of B/E and assays in lower vertebrates, predictive of human health outcomes. These assays will be prioritized for validation at OECD (Organization for Economic Cooperation and Development) level. ERGO will re-think ED testing strategies from in silico methods to in vivo testing and develop, optimize and validate existing in vivo and early life-stage OECD guidelines, as well as new in vitro protocols for THD. This strategy will reduce requirements for animal testing by preventing duplication of testing in mammals and non-mammalian vertebrates and increase the screening capacity to enable more chemicals to be tested for ED properties.
ER -
HOLBECH, Henrik, Peter MATTHIESSEN, Martin HANSEN, Gerrit SCHUURMANN, Dries KNAPEN, Marieke REUVER, Frederic FLAMANT, Laurent SACHS, Werner KLOAS, Klára HILSCHEROVÁ, Marc LEONARD, Juergen ARNING, Volker STRAUSS, Taisen IGUCHI a Lisa BAUMANN. ERGO: Breaking Down the Wall between Human Health and Environmental Testing of Endocrine Disrupters. \textit{International Journal of Molecular Sciences}. Basel: Multidisciplinary Digital Publishing Institute, 2020, roč.~21, č.~8, s.~1-18. ISSN~1422-0067. Dostupné z: https://dx.doi.org/10.3390/ijms21082954.
|
